Consequently, the inhibition of HER2 tyrosine kinase activity is explored therapeutically in many cancers by employing low molecular weight tyrosine kinase inhibitors or monoclonal antibodies that block receptors, ligand binding or receptor dimerization (for review, see e.g., [6,7,8]). This evidence concerns the gene ERBB2 and cancer.